Showing results (11-20 of 9,038) with videos related to

Sort By:
Pageof 904
Rheumatology (Oxford, England)|April 20, 2001
Interleukin-6 promoter polymorphism (--174 G/C) in Caucasian German patients with systemic lupus erythematosusH Schotte, B Schlüter, S Rust, et al.
Rheumatology (Oxford, England)|April 20, 2001
Measurement of joint space width in hip osteoarthritis: influence of joint positioning and radiographic procedureG R Auleley, A Duche, J L Drape, et al.
Rheumatology (Oxford, England)|April 20, 2001
Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosusG Schett, U Firbas, W Füreder, et al.
Rheumatology (Oxford, England)|April 20, 2001
Physical exercise and risk of severe knee osteoarthritis requiring arthroplastyP Manninen, H Riihimaki, M Heliovaara, et al.
Rheumatology (Oxford, England)|July 4, 2002
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral densityN J Minaur, D Kounali, S Vedi, et al.
Rheumatology (Oxford, England)|July 4, 2002
Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosusG E Katsifis, A G Tzioufas, P G Vlachoyiannopoulos, et al.
Rheumatology (Oxford, England)|July 4, 2002
Role of cholecystokinin-8 in nerve growth factor and nerve growth factor mRNA expression in carrageenan-induced joint inflammation in adult ratsL Manni, T Lundeberg, P Tirassa, et al.
Rheumatology (Oxford, England)|July 4, 2002
The synergistic value of focus score and IgA% score of sublabial salivary gland biopsy for the accuracy of the diagnosis of Sjögren's syndrome: a 10-year comparisonM M Zandbelt, J R M Wentink, P C M de Wilde, et al.
Rheumatology (Oxford, England)|August 14, 2002
Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxibS Steinfeld, P A Bjørke
Rheumatology (Oxford, England)|October 5, 2002
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trialE H S Choy, B Hazleman, M Smith, et al.
Pageof 904